Quick search:
Result | Content | Outlet | Published | Research |
---|---|---|---|---|
Result | Content | Outlet | Published | Research |
1 | AstraZeneca-Daiichi Sankyo's ADC barrels forward as Keytruda combo data make case for lung cancer use | FierceBiotech | 11 hours ago |
|
2 | AstraZeneca's stock is well suited for long-term growth | TipRanks | 5 hours ago |
|
3 | AstraZeneca Outlook Raised as Covid Therapies Offset Vaccine Drop (LON:AZN) | Bloomberg | 12 days ago |
|
4 | AstraZeneca and Daiichi Sankyo sprint to market after FDA clears Enhertu in just two weeks | Endpoints News | 11 hours ago |
|
5 | Late to the CAR-T game, AstraZeneca quietly works on its own off-the-shelf therapies | FierceBiotech | 5 days ago |
|
6 | AstraZeneca reports sales drop for Evusheld. Why is the variant-busting COVID med underachieving? | FiercePharma | 11 days ago |
|
7 | AstraZeneca axes Moderna-partnered, phase 2 heart disease drug plus a Wee inhibitor | FierceBiotech | 12 days ago |
|
8 | Daiichi, AstraZeneca Say Nixed Enhertu Probe Foils Patent Policy | Bloomberg Law | 6 hours ago |
|
9 | Verona, Daiichi Sankyo, AstraZeneca and Kodiak Score Big Wins in Key Diseases | BioSpace | 3 hours ago |
|
10 | AstraZeneca pushes forward with Tagrisso combos, touting PhII data with Hutchmed drug | Endpoints News | 10 hours ago |
|
11 | AstraZeneca says COVID vaccine as effective as mRNA shots in review | Reuters | 28 days ago |
|
12 | Astellas hires ex-AstraZeneca oncology exec as medical chief | FiercePharma | 4 days ago |
|
13 | AstraZeneca: Lifeline Amid Double-Digit Inflation (NASDAQ:AZN) | Seeking Alpha | 24 days ago |
|
14 | AstraZeneca to double number of countries where US biotech arm sells rare disease drugs | Financial Times | 11 days ago |
|
15 | AstraZeneca continues Farxiga push, enlists Health2Sync for a digital approach to diagnosing kidney disease | FiercePharma | 23 days ago |
|
16 | ADRs End Mixed; Amarin, AstraZeneca Trade Actively | MarketWatch | 23 hours ago |
|
17 | Astra's Covid Vaccine Saved Over Six Million Lives in First Year | Bloomberg | 28 days ago |
|
18 | Pieris puts phase 2 cancer drug out on chopping block | FierceBiotech | 5 days ago |
|
19 | AstraZeneca nixes variant-specific COVID vaccines, eyes annual shots | BusinessWorld Online | 6 hours ago |
|
20 | Calquence tablet formulation approved in the US across current indications | AstraZeneca | 5 days ago |
|
21 | AstraZeneca to deliver Covid-19 antibody therapy doses to Switzerland | Pharmaceutical Technology | 20 days ago |
|
22 | Vaxzevria 73% effective at preventing Omicron-related infections after fourth dose, according to real world evidence study in Thailand | AstraZeneca | 23 days ago |
|
23 | AstraZeneca says Lynparza gets EU nod to treat early-stage breast cancer | Reuters | 6 days ago |
|
24 | AstraZeneca (LON:AZN) Given Overweight Rating at JPMorgan Chase & Co. | Defense World | 13 hours ago |
|
25 | AstraZeneca CEO Soriot says to work with new chairman for many years | Reuters | 12 days ago |
|
26 | 5th AstraZeneca Ecosystem annual meeting held in Wuxi | China.org.cn | 2 days ago |
|
27 | AstraZeneca: Q2 2022 Earnings May Not Wow Investors | Steady Growth | 16 days ago |
|
28 | AstraZeneca ramps up Farxiga push in new kidney disease label as it uncovers the challenges of this 'silent disease' | FiercePharma | 26 days ago |
|
29 | POSEIDON Phase III post-hoc exploratory analyses presented at WCLC 2022 | AstraZeneca US | 11 hours ago |
|
30 | AstraZeneca's Enhertu gets broader EU approval for breast cancer | Reuters | 23 days ago |
|
31 | Updated: Study shows AstraZeneca's Covid-19 mAb Evusheld may not work against dominant Omicron strain | Endpoints News | 19 days ago |
|
32 | AstraZeneca's COVID-19 antibody jab approved for adults medically unsuitable for vaccination: HSA | CNA | 8 days ago |
|
33 | FDA Weekly Review: Bayer, Daiichi Sankyo, AstraZeneca, Gamida Cell and More | BioSpace | 2 days ago |
|
34 | Arcutis pulls in a win for its topical version of an old AstraZeneca drug in plaque psoriasis | Endpoints News | 11 days ago |
|
35 | Lynparza phase 3 flops, leading Merck, AZ to end trial | FiercePharma | 22 days ago |
|
36 | Cholesteatoma Market Size, Current and Future | Eli Lilly, AstraZeneca, Company – Shanghaiist | Shanghaiist | 8 hours ago |
|
37 | AstraZeneca Standalone June 2022 Net Sales at Rs 232.33 crore, up 32.46% Y-o-Y | Moneycontrol | 1 day ago |
|
38 | AstraZeneca, Accenture, AWS and Clalit Health Services launch BeyondBio SCALE startup program | CTech | 7 days ago |
|
39 | AstraZeneca PLC (NASDAQ:AZN) Shares Purchased by Victory Capital Management Inc. | Defense World | 3 days ago |
|
40 | Pharyngoconjunctival Fever Market Is Expected to Boom: Pfizer Inc., Eli Lilly, AstraZeneca – Shanghaiist | Shanghaiist | 4 hours ago |
|
41 | Health News Roundup: AstraZeneca's Enhertu wins keenly-anticipated U.S. breast cancer nod; Explainer: Monkeypox in the U.S. | Where could it spread next? and more | 2 days ago |
|
42 | Senior awaits compensation after rare AstraZeneca vaccine complication | CBC.ca | 4 days ago |
|
43 | Vinflunine Market Set to Witness Explosive Growth by 2029 | AstraZeneca, Mylan N.V, Johnson & Johnson Private Limited – Shanghaiist | Shanghaiist | 6 hours ago |
|
44 | Antiplatelet Drugs Market 2022 Is Growing Worldwide | The Medicines Company, AstraZeneca, The Medicines Company, Portola Pharmaceuticals – Shanghaiist | Shanghaiist | 18 hours ago |
|
45 | Gastritis Treatment Market Booming Worldwide With Leading Key Players -Pfizer, AstraZeneca, Novartis, Cipla, Abbott Laboratories, Microbiotix, Reddy`s Laboratories, Lupin Ltd, Perrigo Pharmaceutical, Sun Pharmaceutical Industries – Shanghaiist | Shanghaiist | 16 hours ago |
|
46 | Antidepressants Drugs Market Analysis by Top Key Players Pfizer, AstraZeneca, Eli Lilly and Company – Shanghaiist | Shanghaiist | 13 hours ago |
|
47 | Endotracheal and Tracheostomy Tube Market to Witness Huge Growth by 2029 | AstraZeneca, GSK plc, Boehringer Ingelheim International GmbH – Shanghaiist | Shanghaiist | 9 hours ago |
|
48 | Melanocortin Receptor 4 Market 2022 to See Huge Growth by 2029 | AstraZeneca Plc, Mallinckrodt Plc, Obexia AG, Palatin Technologies – Shanghaiist | Shanghaiist | 11 hours ago |
|
49 | AstraZeneca launches Healthy Heart Africa programme to control hypertension | Businessday | 5 days ago |
|
50 | LAMEA Peptide Therapeutics Market Report 2022: Featuring Key Players Eli Lilly And Company, AstraZeneca, Pfizer, GlaxoSmithKline & Others | ResearchAndMarkets.com | 5 days ago |
|
51 | Heart Failure Drugs: Market 2022 Is Booming Worldwide | Bayer, AstraZeneca, Teva Pharmaceutical industries, Gilead – Shanghaiist | Shanghaiist | 14 hours ago |
|
52 | Global Oncology Precision Medicine Market Report 2022: Featuring Key Players F. Hoffmann | La Roche, Novartis, Bristol-Myers Squibb, AstraZeneca & Eli Lily and Co | 13 hours ago |
|
53 | Sinusitis Drugs Market 2022 – Top Industry Players as Sanofi, Bayer, Pfizer, AstraZeneca – Shanghaiist | Shanghaiist | 17 hours ago |
|
54 | Malignant Mesothelioma Market 2022 Top Companies, New Technology, Demand and Opportunity – AstraZeneca, Bristol-Myers Squibb, Roche, Merck – Shanghaiist | Shanghaiist | 17 hours ago |
|
55 | Dental Anesthesia Market Is Booming Worldwide | Abbott, Baxter, ASPEN Group, AstraZeneca, Aspen Global Incorporated(AGI) and more – Shanghaiist | Shanghaiist | 14 hours ago |
|
56 | Diabetes Drugs Market 2022 Development Factors – Sanofi, AstraZeneca, Bayer, Biocon – Shanghaiist | Shanghaiist | 18 hours ago |
|
57 | AstraZeneca Nexium Suits Should Overcome Preemption Challenge | Bloomberg Law | 9 days ago |
|
58 | PARP Inhibitor Market – Increasing approvals of innovative drugs molecules | AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline Plc., Pfizer, Inc | Medgadget | 6 days ago |
|
59 | Pelvic Inflammatory Disease (PID) Market to Witness Robust Expansion by 2029 | Mayne Pharma Group Limited, AstraZeneca, Pfizer Inc – Shanghaiist | Shanghaiist | 4 hours ago |
|
60 | Amid $1B downsizing, Biogen lists Boston-area office space for sublease | FiercePharma | 7 hours ago |
|
61 | Formoterol Market Statistical Forecast, Trade Analysis 2022 –AstraZeneca, Merck, Novartis, Physicians Total Care, Mylan – Shanghaiist | Shanghaiist | 2 days ago |
|
62 | Meningococcal Disease Vaccine Market Worldwide Industry Analysis, Future Demand and Forecast till 2029 |AstraZeneca, Mylan N.V, Johnson & Johnson Private Limited – Shanghaiist | Shanghaiist | 8 hours ago |
|
63 | Performance Enhancing Drugs Market 2022 key developmental strategies implemented by the key players:Taj Pharmaceuticals, Balkan Pharmaceuticals, Bayer, AstraZeneca, Novo Nordisk, BrainAlert, Douglas Laboratories, Onnit Labs, Eli Lilly And Company | Shanghaiist | 10 hours ago |
|
64 | AstraZeneca says its COVID shot still has role despite global glut | Reuters | 3 months ago |
|
65 | AstraZeneca's ambitious vaccine dreams are finally, officially dead | STAT | 3 months ago |
|
66 | AstraZeneca COVID drug neutralises Omicron sub-variants in lab study | Reuters | 5 months ago |
|
67 | AstraZeneca dumps late-phase, next-gen COVID-19 vaccine, calling time on a beta player in an omicron world | FierceBiotech | 6 months ago |
|
68 | AstraZeneca to acquire TeneoTwo and its clinical-stage T-cell engager, strengthening haematological cancer pipeline | AstraZeneca | 1 month ago |
|
69 | AstraZeneca to supply the US government with an additional one million doses of EVUSHELD long-acting antibody combination for the prevention of COVID-19 | AstraZeneca US | 6 months ago |
|
70 | AstraZeneca weighs spinning out COVID-19 products into separate company: Bloomberg | FiercePharma | 8 months ago |
|
71 | AstraZeneca bags pan-variant COVID antibodies from stealthy biotech | FierceBiotech | 3 months ago |
|
72 | AstraZeneca's touts Evusheld treatment data for COVID | FiercePharma | 2 months ago |
|
73 | Exclusive: Short AstraZeneca shelf life complicates COVID vaccine rollout to world's poorest | Reuters | 6 months ago |
|
74 | AstraZeneca launches first COVID drug DTC ad with Evusheld | FiercePharma | 2 months ago |
|
75 | AstraZeneca ready to scrap plans for U.S. approval of COVID shot | FT | 5 months ago |
|
76 | AstraZeneca takes stake in a start-up that helps doctors conduct clinical trials virtually | CNBC | 5 months ago |
|
77 | AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts | AstraZeneca | 3 months ago |
|
78 | AstraZeneca CEO snared more than $18M last year as his company worked through highs and lows of vaccine launch | FiercePharma | 6 months ago |
|
79 | AstraZeneca's COVID-19 antibody combo Evusheld posted a late-stage win | FiercePharma | 4 months ago |
|
80 | What happened to the AstraZeneca vaccine? Now rare in rich countries, it’s still saving lives around the world | The Conversation Indonesia | 3 months ago |
|
81 | AstraZeneca's COVID vaccine sales reached $4B last year, but don't expect that much in 2022 | FiercePharma | 6 months ago |
|
82 | AstraZeneca aims to transform the oncology treatment landscape with diverse early pipeline and novel combinations at AACR | AstraZeneca | 4 months ago |
|
83 | AstraZeneca Will Ax Its US Workers' Pension Plan This Year | Bloomberg Law | 6 months ago |
|
84 | AstraZeneca escapes 1 of 2 Seroquel pay-for-delay claims | FiercePharma | 1 month ago |
|
85 | AstraZeneca sells another half-million doses of its COVID-19 antibody combo to the US | FiercePharma | 7 months ago |
|
86 | AstraZeneca's Evusheld becomes first FDA-authorized COVID antibody to protect the immunocompromised before exposure | FiercePharma | 8 months ago |
|
87 | AstraZeneca's antibody combination, Evusheld (tixagevimab co-packaged with cilgavimab) authorised for use in Great Britain for pre-exposure prophylaxis (prevention) of COVID-19 | AstraZeneca | 5 months ago |
|
88 | GSK Poaches Top AstraZeneca Dealmakers to Boost Drug Pipeline | Bloomberg | 1 month ago |
|
89 | Poor countries reject COVID vaccines from AstraZeneca because of shorter shelf life: report | FiercePharma | 4 months ago |
|
90 | AstraZeneca and Scorpion Therapeutics enter agreement to discover, develop and commercialise novel cancer treatments against 'undruggable' targets | AstraZeneca | 7 months ago |
|
91 | AstraZeneca sees higher 2022 sales even as COVID boost wanes | Reuters | 6 months ago |
|
92 | Evusheld significantly prevented COVID-19 disease progression or death in TACKLE Phase III treatment trial | AstraZeneca | 2 months ago |
|
93 | Poorer nations shun AstraZeneca COVID vaccine | document | 4 months ago |
|
94 | Annual report 2021 | AstraZeneca | 2 months ago |
|
95 | AstraZeneca says early trial data indicates third dose helps against Omicron | Reuters | 7 months ago |
|
96 | AstraZeneca progresses Ambition Zero Carbon programme with Honeywell partnership to develop next-generation respiratory inhalers | AstraZeneca | 6 months ago |
|
97 | AstraZeneca Wins Bid to Quash HHS's Drug Discount Demand | Bloomberg Law | 6 months ago |
|
98 | Oxford will continue to make COVID shots for AZ 'as needed' | FiercePharma | 1 month ago |
|
99 | AstraZeneca throws open doors to new ideas in global postdoc challenge | FierceBiotech | 5 months ago |
|
100 | Equitable access at AstraZeneca | AstraZeneca | 2 months ago |
|